A rally in the shares stalled around $180 in December and early January.
These stocks are displaying bearish tendencies based on their technical patterns.
Let's see how to trade GlycoMimetics, a clinical-stage drug developer focused on a type of cancer treatment.
We have two price target areas for this biopharmaceutical firm.
An oncology and a oil & gas concern, new names on my list, have my attention.
Let's check the charts on this clinical stage drug developer.
These names are off to good starts to 2023 and could have more room to run.
Let's check the charts and indicators.
There are signs that M&A deal activity will pick up in the sector after a couple of subpar years.
Industry experts share their favorite biotech plays for this year.